Hospital
Blanchard Valley Regional Health Center
Blanchard Valley Regional Health Center was paid $1.37M by Medicaid between Jan 2018 and Dec 2024, across 85 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoBLANCHARD VALLEY REGIONAL HEALTH CENTER
BLUFFTON, OH 45817
BLUFFTON, OH 45817
33aNPI1831137827assigned 06/03/2006
33bProvider typeCritical Access Hospital
28Total paid$1.37M
24GClaims39,091
24DCodes billed85
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#24 of 26
Median peer was paid$5.33M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,001 | $73K | |
| 2019 | 2,837 | $66K | |
| 2020 | 1,364 | $59K | |
| 2021 | 2,491 | $123K | |
| 2022 | 3,126 | $151K | |
| 2023 | 16,690 | $519K | |
| 2024incomplete | 10,582 | $385K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 4,124 | 3,569 | $462K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 2,508 | 2,064 | $315K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.7% | 329 | 240 | $133K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 265 | 211 | $75K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 468 | 379 | $72K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 65 | 40 | $29K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 113 | 92 | $28K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 1,043 | 912 | $23K |
| 64493 | 1.6% | 71 | 65 | $22K | |
| 27096 | 1.2% | 54 | 48 | $16K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 159 | 125 | $16K |
| 80053 | Comprehensive metabolic panel | 1.1% | 2,094 | 1,733 | $15K |
73 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 316 | $13K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,568 | $10K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 146 | $10K |
| 87081 | <1% | 564 | $10K | |
| 80061 | Lipid panel | <1% | 487 | $9K |
| 64635 | <1% | 51 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 162 | $8K |
| 64636 | <1% | 58 | $8K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,384 | $7K |
| 87088 | <1% | 449 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 548 | $7K |
| J3490 | Unclassified drugs | <1% | 903 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 245 | $6K |
| 85027 | <1% | 448 | $5K | |
| 64494 | <1% | 72 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,068 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 191 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 162 | $4K |
| 73630 | <1% | 73 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 591 | $4K |
| 84439 | <1% | 286 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 123 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 596 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 94 | $3K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 70 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 798 | $1K |
| 81001 | <1% | 1,191 | $1K | |
| 87077 | <1% | 119 | $1K | |
| 83735 | <1% | 213 | $780.76 | |
| 71045 | Radiologic examination, chest; single view | <1% | 299 | $737.96 |
| 85610 | <1% | 133 | $687.04 | |
| 87660 | <1% | 29 | $681.88 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 830 | $592.48 |
| 64490 | <1% | 15 | $539.54 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 573 | $525.33 |
| 82607 | <1% | 24 | $492.89 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 29 | $443.93 |
| 86901 | <1% | 13 | $376.56 | |
| 83690 | <1% | 553 | $358.50 | |
| 80076 | <1% | 30 | $348.54 | |
| 87480 | <1% | 29 | $289.12 | |
| 01936 | <1% | 19 | $276.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 471 | $274.44 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 137 | $267.37 |
| 86780 | <1% | 15 | $249.10 | |
| 87510 | <1% | 29 | $222.40 | |
| 86850 | <1% | 13 | $188.27 | |
| 84484 | <1% | 214 | $177.96 | |
| 86900 | <1% | 12 | $166.96 | |
| 86803 | <1% | 15 | $163.64 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 251 | $140.36 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 352 | $127.00 |
| 73610 | <1% | 16 | $122.13 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 269 | $102.63 |
| 81025 | <1% | 241 | $97.01 | |
| 84703 | <1% | 57 | $60.59 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,112 | $45.15 |
| 82962 | <1% | 915 | $43.92 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 181 | $27.50 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,379 | $21.59 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 271 | $16.23 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 347 | $9.03 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 256 | $7.44 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 277 | $5.59 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 464 | $3.58 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 479 | $3.09 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 467 | $0.44 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 686 | $0.41 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 158 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 28 | $0.00 |
| 87634 | 0% | 23 | $0.00 | |
| 99152 | 0% | 61 | $0.00 | |
| 00731 | 0% | 50 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCYTLAK, DAVE (VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Blanchard Valley Regional Health Center | Findlay, OH | $24.72M |
| Blanchard Valley Regional Health Center | Findlay, OH | $185K |
| Blanchard Valley Regional Health Center | Bluffton, OH | $113K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.